BIOHAVEN LTD

Biohaven Ltd. has secured a $600 million funding agreement with Oberland Capital, providing non-dilutive capital to support its research and development efforts, particularly in securing U.S. approval for its troriluzole product.

Biohaven Ltd experienced a rollercoaster week, marked by a major financial boost from Oberland Capital, but also challenges including a stock price drop and withdrawal of its marketing application from the European Medicines Agency.

Biohaven Ltd.’s stock prices plummet after the company withdraws its Dazluma application in the European Union, sparking investor concerns and potential regulatory hurdles.